Clobazam is effective as Add-on AED in Partial Onset Seizures
Abstract number :
1.298
Submission category :
7. Antiepileptic Drugs / 7C. Cohort Studies
Year :
2017
Submission ID :
341961
Source :
www.aesnet.org
Presentation date :
12/2/2017 5:02:24 PM
Published date :
Nov 20, 2017, 11:02 AM
Authors :
Aashit Shah, Wayne State University, Detroit Medical Center; James Bathe, Wayne State University, Detroit Medical Center; Maysaa Basha, Wayne State University, Detroit Medical Center; Deepti Zutshi, W; and Rohit Marawar, Wayne State University, Detroit Me
Rationale: In spite of several new antiepileptic drugs (AED), over 30% of the patients with partial onset seizures (POS) remain medically refractory. Clobazam (CLB) is approved by FDA for treatment of seizures in patients with Lennox Gestaut syndrome. It is approved and being used in other countries for other type of seizures including POS. Methods: We retrospectively reviewed information on adults treated in our comprehensive epilepsy program clinic. Any patient who was started on CLB during study period (2014-2015) were included in the study. If diagnosis of LGS or primary generalized epilepsy, and/or lack of follow-up information for at least one year, the patient was excluded. Following information was gathered from all qualifying patients: Age, Sex, Race, seizure duration, etiology, seizure frequency, dose of AEDs, introduction of a new AED, side effects of AED at each time point of 3 months, 6 months and 1 year (or the closest available appointment). The efficacy was tabulated as reduction in seizure frequency from the baseline; 90% reduction or seizure free. If CLB was not initiated or discontinued during study period, the reason for discontinuation was recorded as insurance/personal, lack of efficacy or side effects. Results: Total of 32 patients were identified, 4 of which were excluded for diagnosis of LGS. Of the remaining 28 patients, 8 did not start CLB due to insurance/personal reason. Hence, information from total of 20 patients was analyzed (see Table). Discontinuation were due to following reasons; at 3 months 2 discontinued one due to aggressiveness other due to rash; at 6months 1 due to dizziness; at 1 year 2 died from SUDEP/status (total 5 discontinued). The 50% responder rate was 50%, 60% and 45% at 3 mnth, 6 mnth and 1 yr. Greater than 90% seizure reduction was in 25%, 30%, 25% at 3 mnth, 6 mnth and 1 yr. Seizure freedom was achieved in 10%, 15%, 10% at 3 mnth, 6 mnth and 1 yr. Conclusions: Clobazam is effective in patients with medically refractory partial onset seizures. Funding: The study is funded by Lundbeck.
Antiepileptic Drugs